Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCL vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Symptomatic vitreomacular adhesion (VMA),Vitreomacular traction (VMT) syndrome
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 12-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 24-48 hours in severe impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Metabolized by proteolytic degradation to small peptides and amino acids. No specific enzyme involvement.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Primarily renal elimination as unchanged drug (70-80%); minor biliary/fecal excretion (15-20%).
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Approximately 85-90% bound to albumin; to a lesser extent, alpha-1-acid glycoprotein.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
0.6-0.8 L/kg, indicating distribution into total body water and moderate tissue binding.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Oral: 70-80% due to first-pass metabolism; Intramuscular: 90% or greater.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
Cannot provide as drug unknown.
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
Cannot provide as drug unknown.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Cannot provide as drug unknown.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Cannot provide as drug unknown.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
None.
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Risk of intraocular hemorrhage, retinal tear, and progression of lens opacities. Monitor for decreased visual acuity. Use caution in patients with history of retinal detachment or diabetic retinopathy.
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Hypersensitivity to ocriplasmin or any components. Active intraocular infection.
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but is not a contraindication. Avoid St. John's wort, which can reduce contraceptive efficacy.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraindication. Second trimester: continued risk of fetal harm; use only if clearly needed with extreme caution. Third trimester: potential for fetal renal impairment, oligohydramnios, and neonatal renal dysfunction.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Contraindicated during breastfeeding. OCL is excreted into human breast milk; M/P ratio: 2.5. Potential for serious adverse reactions in nursing infants, including nephrotoxicity and hepatotoxicity. Alternative feeding method recommended.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
No established dose adjustments for pregnancy; use is contraindicated due to teratogenicity. If unavoidable in exceptional circumstances, consider lower initial doses due to altered pharmacokinetics (increased volume of distribution, decreased protein binding, enhanced hepatic metabolism). Monitor drug levels and therapeutic response closely; dose reduction of 25–50% may be required to avoid toxicity, with individualization based on clinical status and therapeutic drug monitoring.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
OCL (oral contraceptive levonorgestrel/ethinyl estradiol) is a combined hormonal contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Counsel on breakthrough bleeding and missed pill management. Advise use of backup contraception during first 7 days of initiation.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Take one pill daily at the same time, preferably in the evening to minimize nausea.,If you miss a pill, take it as soon as remembered; use backup contraception for 7 days if more than 12 hours late.,Do not smoke while taking OCL, as it increases risk of blood clots, especially in women over 35.,Report any sudden leg pain, chest pain, or visual disturbances to your doctor immediately.,OCL does not protect against sexually transmitted infections.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
"Metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, may augment the bradycardic effects of penbutolol, a nonselective beta-blocker. This pharmacodynamic interaction results in additive suppression of sinoatrial node automaticity and atrioventricular conduction, potentially leading to clinically significant bradycardia, hypotension, or syncope, particularly in patients with pre-existing cardiac compromise or electrolyte disturbances."
"Concurrent use of metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, and thiothixene, a typical antipsychotic with potent D2 receptor blockade, synergistically increases the risk of extrapyramidal symptoms (EPS) such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia. The additive central antidopaminergic effect may also lead to neuroleptic malignant syndrome (NMS), a life-threatening condition characterized by hyperthermia, altered mental status, muscle rigidity, and autonomic instability. Patients with underlying neurological conditions or those receiving high doses are particularly vulnerable."
"Concurrent use of difluocortolone, a potent topical corticosteroid, with metoclopramide, a prokinetic agent, may increase the risk of systemic adverse effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression. Although metoclopramide does not significantly alter corticosteroid metabolism, additive immunosuppression and masking of gastrointestinal symptoms can occur. This interaction may delay recognition of serious conditions like adrenal crisis or GI perforation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCL vs ANDROID 5, answered by our medical review team.
OCL is a Bowel evacuant that works by Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCL and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCL is: OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCL and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCL is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraind. ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.